Gilead, Parker Institute grab stakes in Penn immunotherapy spinout's $100 million round
January 23, 2018 at 10:21 AM EST
Initially focused on cancer, the Philadelphia-based company started in the lab of University of Pennsylvania T-cell immunotherapy pioneer Dr. Carl June.
